Cvs Dividends - CVSG

Cvs Dividends - CVSG

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Cvs Group Plc CVSG London Ordinary Share GB00B2863827 ORD 0.2P
  Price Change Price Change % Stock Price Last Trade
-25.00 -1.17% 2,120.00 16:29:34
Open Price Low Price High Price Close Price Previous Close
2,125.00 2,110.00 2,160.00 2,120.00 2,145.00
more quote information »
Industry Sector

Cvs CVSG Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

whatja: Sky was reporting that Medivet is for sale @ £1bn. They operate 300 Sites. In the past Medivet and CVSG could have been merged, but I doubt either can buy the other for cash. Expect a bigger player like Mars to win the auction. Nevertheless it will provide a benchmark for valuing CVSG.
tomps2: CVS Group plc H1 2021 Results Presentation, given by Richard Fairman, CEO, Robin Alfonso, CFO and Ben Jacklin, COO on 25th March 2021 Watch the video here: Https:// Or listen to the podcast version here: Https://
energeticbacker: The growth in pet ownership over lockdown and owner’s desires to keep their pets fit and healthy has been great news for the pet care sector. However, who are going to be the long-term winners from the current pet boom? Investor’s Champion’s research highlights some terrific companies which should continue to do well, including a star performer. #ancr #chwy #cvsg #elan #idxx #nesn #pets #zts
1jat: I’m sticking with cvsg
whatja: It has been a topsy turvy day. CVSG has been relatively stable.....So maybe these are sold to chase the Covid shares that might gain.
1jat: Lots to like with an excellent update on the first two months. Anecdotally the vets are very busy, they are operating safely and profitably. IMHO this is looking like a much stronger business. I expect there will be a number of small practices that will want to sell up and CVSG will be paying less to acquire them. One to believe in again.
waldron: Dividends Having taken advantage of government support during the COVID-19 pandemic, and in line with the approach taken by many other companies, the Board does not intend to recommend the payment of a final dividend. Shareholder engagement Prior to COVID-19, the Directors regularly held one-to-one meetings and calls with shareholders. Although the Directors temporarily suspended issuing guidance due to COVID-19, we continue our regular interactions with shareholders. Outlook CVS operates in a sector with favourable market and consumer trends, with pet owners who remain willing to spend money on their pets and medical enhancements increasing the range of services we can offer. COVID-19 severely impacted our business in the last quarter of this financial year, reducing our revenues. CVS was eligible for, and successfully accessed, the Coronavirus Job Retention Scheme and placed over half of all employees on furlough. CVS also accessed support from taxation authorities in the UK and the Netherlands. I am pleased to say that post year-end, all of our employees have now returned from furlough leave. As described more fully in the CEO's statement, trading in the first two months has been encouraging. Despite continued uncertainty over Brexit, I am confident that CVS is well positioned to avoid significant adverse impacts from the UK's decision to exit the EU. Pharmaceutical manufacturers and wholesalers are increasing their stock levels in order to reduce the risk of supply shortages and, following the acquisition of Vet Direct in 2018, CVS now controls more directly its equipment and consumables supplies. Looking ahead, we welcome the positive environment for acquisitions and are well placed to take advantage of growth opportunities. The pace of growth in the UK economy may be impacted by Brexit and COVID-19 uncertainty, but the veterinary sector has proven to be resilient in past periods of economic downturn and the Board believes that CVS is well-positioned to withstand any potential future downturn. Richard Connell Chairman 24 September 2020
misca2: Final dividend Having taken advantage of government support, and in line with the approach taken by many other companies, the Board does not intend to recommend the payment of a final dividend. Outlook: post COVID-19 lockdown Since April 2020 CVS have, where possible, reopened practices and un-furloughed employees. We are pleased that by the financial year end the majority of our practices were open and the majority of employees have returned to work. The Board is confident that the actions taken have been in the best interest of both our employees and our clients and have not had a detrimental impact on the number of active clients that the Group services. Alongside the re-opening of our practices, we have taken the decision to permanently close 33 sites in the Group, the majority of which are small branches of larger practice groups which were either marginal or loss-making. The Board is confident that the majority of clients formerly served by these sites will continue to be served by our larger and better equipped CVS veterinary sites close by. CVS is a diversified business with strong coverage in the UK and an established platform in the Republic of Ireland and the Netherlands. The Group provides an essential service to companion animals and supports the maintenance of the food supply chain. We continue to maintain 415,000 Healthy Pet Club subscription memberships which provide recurring revenue and which continue to be a resilient source of cashflow. Animed Direct, our online pharmacy and retail business, has performed well throughout the financial year and has benefitted from an increase in demand during the lockdown period. Leverage has materially reduced from the 1.61x reported at the end of February 2020 due to the actions taken by the Board to both protect the business and preserve cash (30 June 2019: 2.08x). The Company continues to refrain from giving guidance to analysts. Whilst there is ongoing COVID-19 uncertainty with the potential risk of further future lockdowns, the Board is confident that the business is robustly managed and well positioned to drive further increases in shareholder value.
misca2: Strong resistence it seems at 1019p Https://
florenceorbis: Read more in our update of announcements here: Https://
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210519 00:42:00